Pfizer, Inc. (PFE) Shares Sold by Carlton Hofferkamp & Jenks Wealth Management LLC
Carlton Hofferkamp & Jenks Wealth Management LLC cut its stake in shares of Pfizer, Inc. (NYSE:PFE) by 0.0% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 66,662 shares of the biopharmaceutical company’s stock after selling 24 shares during the period. Pfizer comprises approximately 1.5% of Carlton Hofferkamp & Jenks Wealth Management LLC’s holdings, making the stock its 13th largest position. Carlton Hofferkamp & Jenks Wealth Management LLC’s holdings in Pfizer were worth $2,239,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently made changes to their positions in PFE. Boston Partners lifted its stake in Pfizer by 7.3% in the first quarter. Boston Partners now owns 24,263,989 shares of the biopharmaceutical company’s stock valued at $830,071,000 after acquiring an additional 1,649,801 shares during the last quarter. Bank of Nova Scotia lifted its stake in Pfizer by 325.9% in the first quarter. Bank of Nova Scotia now owns 1,934,514 shares of the biopharmaceutical company’s stock valued at $66,180,000 after acquiring an additional 1,480,258 shares during the last quarter. State of Tennessee Treasury Department lifted its stake in Pfizer by 22.7% in the first quarter. State of Tennessee Treasury Department now owns 4,891,784 shares of the biopharmaceutical company’s stock valued at $167,348,000 after acquiring an additional 904,413 shares during the last quarter. Achmea Investment Management B.V. acquired a new stake in Pfizer in the first quarter valued at approximately $25,502,000. Finally, Oppenheimer Asset Management Inc. acquired a new stake in Pfizer in the first quarter valued at approximately $21,605,000. 69.00% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “Pfizer, Inc. (PFE) Shares Sold by Carlton Hofferkamp & Jenks Wealth Management LLC” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/19/pfizer-inc-pfe-shares-sold-by-carlton-hofferkamp-jenks-wealth-management-llc.html.
Shares of Pfizer, Inc. (NYSE:PFE) traded down 0.267% during midday trading on Tuesday, reaching $35.455. 5,546,272 shares of the company’s stock traded hands. The stock has a market cap of $210.86 billion, a price-to-earnings ratio of 25.936 and a beta of 1.00. Pfizer, Inc. has a 52-week low of $29.83 and a 52-week high of $35.84. The stock has a 50 day moving average of $33.71 and a 200-day moving average of $33.53.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The company had revenue of $12.90 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter last year, the firm earned $0.64 earnings per share. The company’s revenue was down 1.9% on a year-over-year basis. On average, equities research analysts expect that Pfizer, Inc. will post $2.56 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Friday, September 1st. Stockholders of record on Friday, August 4th were issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.60%. The ex-dividend date was Wednesday, August 2nd. Pfizer’s dividend payout ratio is currently 94.12%.
PFE has been the subject of a number of analyst reports. ValuEngine cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Morgan Stanley reiterated a “neutral” rating and issued a $35.00 target price (down from $38.00) on shares of Pfizer in a research note on Monday, June 12th. Jefferies Group LLC reiterated a “neutral” rating and issued a $34.00 target price on shares of Pfizer in a research note on Friday, June 16th. BidaskClub upgraded shares of Pfizer from a “strong sell” rating to a “sell” rating in a research note on Friday, June 23rd. Finally, Cowen and Company set a $43.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Monday, July 10th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $37.83.
In other news, insider Sally Susman sold 38,230 shares of Pfizer stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the completion of the sale, the insider now owns 145,649 shares of the company’s stock, valued at $5,097,715. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Ian C. Read sold 197,168 shares of Pfizer stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $34.00, for a total value of $6,703,712.00. Following the sale, the chief executive officer now directly owns 580,318 shares of the company’s stock, valued at approximately $19,730,812. The disclosure for this sale can be found here. Insiders have sold 464,521 shares of company stock valued at $15,813,961 in the last three months. Insiders own 0.06% of the company’s stock.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.